Allergy Shot Market

Allergy Shot Market Outlook (2024 to 2034)

The global allergy shot market is expected to reach a valuation of US$ 1.84 billion in 2024 and further expand at a CAGR of 6.1% to end up at US$ 3.34 billion by 2034.

An allergy occurs when the body's immune system reacts too strongly to an exogenous item, such as food, pollen, fur, or dust. During allergy immunotherapy, the body is exposed to small amounts of allergens to stimulate the production of antibodies against them. This therapy is an efficient method to treat allergies by regularly exposing the body to specific allergens in low doses.

• The World Allergy Organization estimates that currently, 10 to 30 percent of people worldwide suffer from some form of allergy.

Factors such as population growth, industrialization, advancements in healthcare and medicine, and the introduction of new immunotherapeutic treatments are driving the global market for allergy immunotherapy. Recent regulatory approvals, including those for oral dissolvable tablets, are also expected to further expand the market for allergy shots.

Allergy symptoms can range from mild, such as hives or a rash, to more severe symptoms like itching, a runny nose, and watery or red eyes. Treatment options for allergies vary depending on the specific allergen sensitivity of the patient. Over-the-counter medications are available for mild allergies, with antihistamines being commonly used. Decongestants provide short-term relief.

For skin reactions like redness and irritation due to allergies, creams, and lotions are often used. Inflammation caused by an allergic reaction can be reduced with steroid treatments. Natural remedies, over-the-counter pharmaceuticals, and prescription medications are also options for managing seasonal allergies.

Allergy shots decrease sensitivity to allergens. In individuals with allergies, the immune system can overreact to harmless substances. Common triggers include dust mites, mold, pollen, pet dander, and insect venom. Allergy shots expose the body to small, safe doses of these triggers, similar to vaccination, which helps the immune system build tolerance and reduce allergy symptoms over time.

The benefits of allergy shots include better allergy management, reduced long-term treatment needs, and decreased sensitivity to various allergens. These advantages are expected to drive increased demand for allergy shots, contributing to the expansion of the allergy shot market size in the foreseeable future.

Report Attribute	Detail
Allergy Shot Market Size (2024E)	US$ 1.84 Billion
Forecasted Market Value (2034F)	US$ 3.34 Billion
Global Market Growth Rate (2024 to 2034)	6.1% CAGR
Canada Market Growth Rate (2024 to 2034)	6.4% CAGR
China Market Value (2034F)	US$ 454 Million
North America Market Share (2024E)	39%
East Asia Market Share (2034F)	23.2%
Key Companies Profiled	Circassia; Merck; Allergy Therapeutics; ALK-Abello; Letipharma; HollisterStier Allergy; Aimmune Therapeutics; DBV Technologies; Stallergenes Greer; HAL Allergy Group; Biomay AG.

Why is Demand for Allergy Shots on the Rise Worldwide?

“Increasing Prevalence of Rhinitis Necessitating More Effective Treatments”

• In 2022, research published in Clinical and Translational Allergy indicated that the global median prevalence rates for NAR, AR, and nonspecific rhinitis were 18.1%, 12.0%, and 29.4%, respectively, with variations observed across different regions.
• According to the Centers for Disease Control and Prevention's estimates for 2023, approximately 25.7% of American adults aged 18 and over were expected to experience seasonal allergies, encompassing nearly 31.8% of the adult population.

This trend is being mirrored in other countries worldwide, contributing to allergy shot market growth. Over time, the prevalence of rhinitis continues to increase, driven by a rise in allergic conditions and a growing necessity for more effective treatments. This growing market for allergy injections is also influenced by urbanization and changing lifestyles, which contribute to the emergence of new allergic conditions.

Factors such as pollution levels, unhealthy dietary habits, and alcohol consumption can trigger various allergic responses, including food and skin allergies, thereby potentially boosting the demand for allergy shot therapies.

The market for allergy shots remains dynamic, driven by advancements in recombinant immunotherapies, specialized medications, and other factors. Industry players are continually expanding their product portfolios, customer bases, and global presence through strategies like mergers, acquisitions, partnerships, and collaborative initiatives. These efforts enable them to meet evolving customer needs, maintain competitiveness, and foster collective growth.

• For instance, Nestle Health Science announced in August 2020 its acquisition of Immune Therapeutics' food allergy product line, exemplifying strategic moves aimed at enhancing its market position and addressing growing demands in allergy treatment.

What are the Key Concerns in the Market for Allergy Shots?

“Lengthy Treatment Times Not Favored by Many”

Allergy shots require a lengthy course, typically lasting three to five years, tailored to the allergy type and severity. Many patients discontinue due to treatment duration, age, health, location, and financial constraints, hindering industry growth. Furthermore, the market size is shrinking due to the adverse effects of allergy pills and injections.

• For instance, a 2022 study published in Human Vaccines & Immunotherapeutics reported that over 10% of patients experienced adverse reactions, including mild to severe local symptoms like oral pruritus (25%), throat discomfort (21%), and mild systemic effects like edema or redness at injection sites.

“High Cost of Treatment Coupled with Poor Patient Adherence”

Allergy shots provide numerous benefits, yet patient adherence to treatment is often insufficient due to factors such as limited patient awareness and inadequate funding.

• For instance, a 2022 NCBI paper highlights that discomfort associated with subcutaneous (SCIT) and sublingual treatments, along with side effects, are primary reasons for treatment discontinuation.

High cost of treatment and lack of insurance coverage in some countries are expected to restrict the accessibility of allergy shots.

Country-wise Insights

The market in South Korea is forecasted to expand at a CAGR of 6.2% from 2024 to 2034. The country is set to hold 25.2% of the East Asia allergy shot market share by the end of 2034.

What Makes the United States an Attractive Market for Allergy Shot Manufacturers?

“Advanced Clinical Trials and Huge Investments by Corporates”

Attribute	United States
Market Value (2024E)	US$ 605 Million
Growth Rate (2024 to 2034)	6.5% CAGR
Projected Value (2034F)	US$ 1.14 Billion

Firms in the United States are increasing their spending on developing cutting-edge products that are user-friendly and offer quick results. This is one of the key allergy shot market trends in the country.

• Moonlight Therapeutics, Inc., a biotechnology company investigating therapeutics for food allergies, reported in 2021 that it had received US$ 1.9 million in investment for preclinical studies and product development. This was done to get ready for a clinical trial for the company's principal program in peanut allergy. This financing was made possible by a Phase 2 Small Business grant from the National Institute of Allergy and Infectious Diseases (NIAID), a division of the National Institutes of Health (NIH).

Why are Market Players Flocking China for Future Business Prospects?

“Government Reforms Supporting Access to Quality Healthcare”

Attribute	China
Segment Value (2024E)	US$ 217 Million
Growth Rate (2024 to 2034)	7.6%CAGR
Projected Value (2034F)	US$ 454 Million

China's population is experiencing a significant increase in allergic conditions, driven by urbanization, changing lifestyles, and environmental factors. This rising prevalence of allergies creates a growing demand for effective treatments like allergy shots. The Chinese government has formulated healthcare reforms to enhance access to quality medical services across the country. This supportive regulatory environment encourages market players to invest in innovative allergy treatments

Category-wise Evaluation

Based on product type, sales of odactra are forecast to rise at a CAGR of 5.4% from 2024 to 2034.

Which Type of Immunotherapy Has Gained Prominence in the Market?

“Growing Demand for Subcutaneous Immunotherapy”

Attribute	Subcutaneous Immunotherapy
Segment Value (2024E)	US$ 952 Million
Growth Rate (2024 to 2034)	6.1% CAGR
Projected Value (2034F)	US$ 1.72 Billion

Allergen-specific subcutaneous immunotherapy effectively treats various allergy disorders. The optimal injection site is the mid-posterolateral region of the upper arm. Subcutaneous immunotherapy (SCIT) represents an innovative approach to managing allergic conditions by modifying the underlying immunological mechanisms, thereby reducing symptoms. Its effectiveness and safety in treating stinging insect hypersensitivity, asthma, and allergic rhinitis/rhino-conjunctivitis have been validated in numerous controlled clinical studies.

What is the Main Reason Behind Global Increase in Allergic Rhinitis Cases?

“Rise in Urbanization and Environmental Pollutants”

Attribute	Allergic Rhinitis
Segment Value (2024E)	US$ 784 Million
Growth Rate (2024 to 2034)	6% CAGR
Projected Value (2034F)	US$ 1.41 Billion

Allergy, also referred to as hay fever or allergic rhinitis, is primarily driven by the global increase in allergic rhinitis cases.

• According to a 2022 article in Frontiers of Medicine, approximately 400 million people worldwide suffer from allergic rhinitis (AR), making it a significant global health concern.

The prevalence of AR has risen alongside increasing urbanization and environmental pollutants, which are major contributing factors to this condition's growth over time.

Competitive Landscape

Through expansion, collaborations, new product development, mergers and acquisitions, and other growth tactics, key players in the allergy shot market are adapting themselves to the evolving market trends.

• In October 2023, Itulatek's phase 3 experiment for the treatment of allergic rhino-conjunctivitis brought on by tree pollen was completed, according to ALK.
• In January 2023, HollisterStier Allergy introduced Ultrafiltered Dog, their newest product innovation, to the allergy market. Patients who are sensitive to dogs respond well to the product's diagnosis and therapy.
• In October 2022, Aimmune Therapeutics and Allergy Partners, a specialized allergy practice group, partnered to provide Palforzia, an oral immunotherapy, to patients directly.

Fact.MR provides detailed information about the price points of key allergy shot manufacturers positioned across the world, sales growth, production capacity, and speculative technological expansion, in this updated market report.

Key Segments of Allergy Shot Market Research

• By Product :

  • SLIT Tablets
    • Odactra
    • Grastek
    • Ragwitek
    • Oralair
    • Actair
    • Others
  • Oral
    • Palforzia
    • Others
  • Injections
  • Others

• By Immunotherapy :

  • Sublingual Immunotherapy (SLIT)
  • Subcutaneous Immunotherapy (SCIT)
  • Specific Immunotherapy
  • Others

• By Indication :

  • Allergy Rhinitis
  • Allergic Asthma
  • Food Allergy
  • Atopic Dermatitis
  • Others

• By Allergen :

  • Pollen
    • Grass Pollen
    • Weed Pollen
    • Tree Pollen
  • House Dust Mites (HDMs)
  • Mold
  • Animal Dander
  • Bee Venom
  • Cockroaches/Insects
  • Others

• By Distribution Channel :

  • Institutional Sales
    • Government Hospitals
    • Semi-Government Hospitals
    • Private Hospitals
  • Retail Sales
    • Retail Pharmacy
    • Drug Stores
    • Online Pharmacy

• By Region :

  • North America
  • Latin America
  • Eastern Europe
  • Western Europe
  • East Asia
  • South Asia & Pacific
  • Middle East & Africa